Mounjaro and Blood Pressure: How Tirzepatide Affects Hypertension

Mounjaro and blood pressure have a closer relationship than many patients realise. If you are taking tirzepatide for weight loss and also live with high blood pressure, the evidence suggests your treatment may be doing more than shifting the number on the scales. Clinical trial data consistently shows that Mounjaro lowers both systolic and diastolic blood pressure, offering meaningful cardiovascular benefits alongside weight reduction.

Hypertension affects roughly one in four adults in the UK, and it is significantly more common in people living with obesity. In this article, we review the trial evidence, explain the mechanisms involved, and outline what your doctor should be monitoring while you are on treatment.

Yes. In the SURMOUNT-1 trial, participants treated with tirzepatide for 72 weeks experienced an average reduction of 6.8 mmHg in systolic blood pressure and 4.2 mmHg in diastolic blood pressure compared with placebo. These reductions are clinically significant and comparable to the effect of some first-line antihypertensive medications. Furthermore, the blood pressure improvements were consistent across different baseline blood pressure levels, meaning patients who started with higher readings saw proportionally larger reductions.

To put this in context, a sustained reduction of 5 mmHg in systolic blood pressure is associated with approximately a 10% lower risk of major cardiovascular events over a decade, according to data published in The Lancet. The reductions seen with tirzepatide exceed this threshold at all three doses studied.

Tirzepatide is a dual GIP/GLP-1 receptor agonist. While its primary mechanism targets appetite regulation and glucose metabolism, several pathways contribute to its blood pressure-lowering effects.

The most important factor is weight loss itself. According to stratified analyses of the SURMOUNT-1 trial published in the journal Hypertension, weight loss explained approximately 68% of the systolic blood pressure reduction and 71% of the diastolic reduction. For every kilogram of body weight lost, systolic blood pressure dropped by roughly 0.5 to 1 mmHg. Given that patients on the 15 mg dose lost an average of 22.5% of their body weight, the cumulative effect on blood pressure is substantial.

However, weight loss alone does not account for the full effect. The remaining 30% of the blood pressure reduction appears to come from weight-independent mechanisms. These include improved insulin sensitivity (hyperinsulinaemia promotes sodium retention), reduced systemic inflammation, natriuretic effects (increased sodium excretion by the kidneys), and changes in vascular tone mediated by GLP-1 receptor activity in blood vessel walls.

In particular, GLP-1 receptor activation has been shown to stimulate nitric oxide production in the vascular endothelium, which relaxes blood vessels and reduces peripheral resistance. This direct vascular effect likely explains why blood pressure improvements can begin within the first few weeks of treatment, before substantial weight loss has occurred.

In practical terms, this means Mounjaro offers a dual benefit: patients lose weight, which lowers blood pressure, while the drug itself provides additional cardiovascular protection through direct metabolic and vascular effects.

The evidence for tirzepatide’s blood pressure effects comes primarily from the SURMOUNT clinical trial programme, which enrolled over 10,000 participants with obesity or overweight.

SURMOUNT-1 was the landmark trial. In this study, 2,539 adults without type 2 diabetes received tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks. Blood pressure monitoring showed a rapid decline in both systolic and diastolic readings over the first 24 weeks, followed by stabilisation through to week 72. The net reduction versus placebo was 6.8 mmHg systolic and 4.2 mmHg diastolic at the highest dose.

SURMOUNT-1 Ambulatory Blood Pressure Monitoring (ABPM) substudy provided even more granular data. Using 24-hour ambulatory monitors, researchers confirmed that tirzepatide reduced blood pressure consistently throughout the day and night, not just during clinic visits. This is particularly important because sustained nocturnal blood pressure reduction is associated with lower long-term cardiovascular risk.

Moreover, post-hoc analyses from SURMOUNT-5 presented at the European Society of Cardiology (ESC) confirmed tirzepatide’s superiority over semaglutide across individual cardiovascular risk factors, including systolic blood pressure, LDL cholesterol, and HbA1c. This head-to-head comparison strengthens the case for tirzepatide as a treatment that addresses multiple cardiometabolic risks simultaneously.

The SURMOUNT-1 stratified analyses showed that blood pressure reductions were broadly consistent across all participant subgroups. Nevertheless, certain groups saw particularly meaningful improvements.

Patients with stage 1 or stage 2 hypertension at baseline (systolic blood pressure above 130 mmHg) experienced the largest absolute reductions. In some subgroups, systolic blood pressure fell by more than 10 mmHg, which is enough to meaningfully reduce stroke and heart attack risk over five to ten years.

Similarly, patients with obesity-related comorbidities such as type 2 diabetes, obstructive sleep apnoea, or metabolic syndrome tended to derive greater cardiovascular benefit. This aligns with what we see at CutKilo: patients who have the most to gain metabolically often see the most dramatic improvements across multiple health markers, not just weight.

Of course, even patients with normal baseline blood pressure experienced a modest downward shift. The overall effect was described by the SURMOUNT investigators as “shifting the blood pressure distribution curve to lower levels,” meaning the entire population of treated patients moved towards a healthier range.

For a broader look at how Mounjaro supports cardiovascular health, see our guide to Mounjaro and heart health.

If you are taking Mounjaro and also have high blood pressure, regular monitoring is essential. As your weight decreases, your blood pressure medication requirements may change. In fact, continuing the same antihypertensive dose during significant weight loss can sometimes lead to blood pressure dropping too low, causing symptoms that affect your daily life.

At CutKilo, we recommend the following approach:

• Check your blood pressure at home at least twice a week, ideally in the morning before medication
• Keep a written log and share it with your prescribing doctor at each review
• Report any symptoms of low blood pressure promptly: dizziness on standing, lightheadedness, or feeling faint
• Discuss with your GP whether your antihypertensive medication needs reducing as your weight falls

NICE guidelines (NG136) recommend that blood pressure targets for adults under 80 are below 140/90 mmHg in clinic or below 135/85 mmHg on ambulatory or home monitoring. If your readings consistently fall below 120/80 mmHg while on treatment, your doctor may consider stepping down your antihypertensive dose. This is a routine and expected part of managing blood pressure during medically supervised weight loss.

Low blood pressure (hypotension) is an uncommon but recognised side effect of tirzepatide. In the SURMOUNT trials, low blood pressure adverse events were infrequent overall, though the rate was slightly higher in the tirzepatide group compared with placebo.

The risk is highest in patients who are already taking antihypertensive medications. As Mounjaro drives weight loss and blood pressure falls naturally, the combined effect of the drug plus existing medication can occasionally push blood pressure below a comfortable range. Specifically, patients on multiple antihypertensive agents are at greater risk during the dose titration phase, when weight loss is most rapid.

Dehydration compounds this risk further. Mounjaro can reduce fluid intake (via appetite suppression) and increase fluid loss (via its natriuretic effects). Consequently, staying well hydrated is particularly important for patients on blood pressure medication. Aim for at least 1.5 to 2 litres of water daily, and increase this in warm weather or during exercise.

The MHRA Summary of Product Characteristics (SmPC) for tirzepatide notes that caution is advised in patients taking antihypertensive medications, particularly during the dose titration phase. If you experience persistent dizziness, blurred vision, or fainting, contact your prescribing doctor promptly.

Mounjaro offers a clinically meaningful reduction in blood pressure alongside its weight loss effects. The SURMOUNT trial programme demonstrates a consistent 6 to 7 mmHg drop in systolic blood pressure at the highest dose, with benefits sustained over 72 weeks and confirmed by 24-hour ambulatory monitoring. For patients living with both obesity and hypertension, tirzepatide addresses two serious health concerns simultaneously. If you are already taking blood pressure medication, regular monitoring and dose adjustment discussions with your GP are essential as your weight decreases.

How quickly does Mounjaro lower blood pressure? In the SURMOUNT-1 trial, blood pressure began falling within the first few weeks of treatment, with the most rapid decline occurring over the first 24 weeks. This mirrors the early phase of weight loss when metabolic improvements are most pronounced.

Can I stop my blood pressure tablets if I start Mounjaro? Never stop or adjust blood pressure medication without consulting your doctor. While Mounjaro may reduce your blood pressure enough for your GP to consider lowering your dose, this decision must be based on repeated home readings and clinical assessment.

Does Mounjaro work better than Ozempic for blood pressure? Post-hoc data from SURMOUNT-5, presented at the European Society of Cardiology, showed tirzepatide outperformed semaglutide on systolic blood pressure reduction. However, both medications offer meaningful blood pressure benefits, and the best choice depends on your overall clinical profile.

Is Mounjaro safe if I have very high blood pressure? Tirzepatide has been studied in participants with a range of baseline blood pressures. NICE recommends that severe or uncontrolled hypertension (above 180/120 mmHg) should be stabilised before starting any new treatment. Your prescribing doctor will assess whether your blood pressure is adequately controlled before initiating Mounjaro.

Will my blood pressure go back up if I stop Mounjaro? The blood pressure reduction is closely linked to weight loss. If weight is regained after stopping treatment, blood pressure typically rises again. Maintaining a healthy weight through diet and exercise after stopping Mounjaro is the most effective way to sustain the blood pressure benefits.